1. Home
  2. REAX vs EDIT Comparison

REAX vs EDIT Comparison

Compare REAX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Real Brokerage Inc.

REAX

The Real Brokerage Inc.

HOLD

Current Price

$16.48

Market Cap

435.9M

Sector

N/A

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.57

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAX
EDIT
Founded
2018
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
435.9M
432.8M
IPO Year
2026
2016

Fundamental Metrics

Financial Performance
Metric
REAX
EDIT
Price
$16.48
$2.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
★ $5.49
$5.30
AVG Volume (30 Days)
925.0K
★ 2.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.50
EPS
★ N/A
N/A
Revenue
N/A
★ $31,937,000.00
Revenue This Year
$23.04
N/A
Revenue Next Year
$15.98
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 132.64
52 Week Low
$1.55
$1.66
52 Week High
$28.85
$4.54

Technical Indicators

Market Signals
Indicator
REAX
EDIT
Relative Strength Index (RSI) 53.53 41.00
Support Level $2.10 $2.47
Resistance Level $21.22 $2.77
Average True Range (ATR) 1.62 0.19
MACD -1.00 -0.02
Stochastic Oscillator 31.62 3.73

Price Performance

Historical Comparison
REAX
EDIT

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: